Xspray Pharma AB (publ) (STO:XSPRAY)
10.18
-0.30 (-2.86%)
Nov 20, 2026, 5:29 PM CET
Xspray Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Lucamzi is preparing for a mid-2027 U.S. launch, while Xdivane targets an FDA submission after a Q2 2027 trial readout and a day-one post-patent launch. Restructuring and partner-led launches support a path toward positive cash flow.
-
The FDA's CRL for Dasynoc centers on facility status and a request for more commercial-scale batch data, with no new clinical or product quality concerns. Batch work is being accelerated for a 2026 resubmission, and commercialization plans remain on track pending regulatory clearance.